Status:
WITHDRAWN
Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism
Lead Sponsor:
Charles Drew University of Medicine and Science
Conditions:
Panhypopituitarism
Eligibility:
FEMALE
18-55 years
Brief Summary
The purpose of this study is to determine the blood levels of testosterone gel administered for a week to women with hypopituitarism and determine if this leads to testosterone replacement in a normal...
Detailed Description
The ovaries and the adrenal glands contribute to the daily production of 300 micrograms of testosterone in healthy, menstruating women. The physiologic role of testosterone in women, however, remains ...
Eligibility Criteria
Inclusion
- Women age 18-55
- Hypopituitarism with documented central adrenal and gonadal deficiencies. Serum testosterone level of \< 20 ng/dl or free testosterone \<1.5 pg/ml on conjugated equine estrogen replacement
- No other significant medical condition
- Weight between 80 and 150% of ideal body weight
- Able to provide informed consent
- All races and ethnicities
- All patients regardless of marital status and relationship status
Exclusion
- Physical disabilities that would prevent them from participating in the study
- Current use of testosterone or other androgenic steroids. Patients who are taking testosterone, DHEA or other androgen precursors will discontinue these medications/supplements three months prior to the study.
- Significant cardiopulmonary disease, renal disease (creatinine \> 1.5 mg/dL), diabetes mellitus, uncontrolled hypertension, malignancy (other than basal cell skin carcinoma) or major psychiatric disease. Patients with depression or anxiety on a stable dose of medication will be allowed to enroll.
- Current abuse of illicit drugs or heavy ethanol use
- History of breast or uterine cancer
- Those with significant liver function abnormalities defined as SGOT, SGPT or alkaline phosphatase value of greater than one and one-half times the upper limit of normal in our Clinical Pathology Laboratory or serum bilirubin levels of greater than 2 mg/dl will be excluded.
- Those with history of hyperandrogenic disorders such as hirsutism and polycystic ovary disease will be excluded. These conditions are rare in women with hypopituitarism. Testosterone administration to these patients may exacerbate the underlying disorder.
- Women who are pregnant, seeking to become pregnant in the next 6 months, or breast feeding
- Those who have previously experienced intolerance to other transdermal systems
- Drugs known to alter testosterone production such as Megace or ketoconazole
- Patients with untreated hyperprolactinemia or active Cushing's disease. Patients with treated prolactinoma or Cushing's disease will be allowed to participate in the study.
- Hematocrit \> 50%
- Male sex
- Not willing to answer all questions on surveys
Key Trial Info
Start Date :
August 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2002
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00144404
Start Date
August 1 2002
End Date
August 1 2002
Last Update
April 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charles R. Drew University
Los Angeles, California, United States, 90059